VAXIL BIO LTD (VXL.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:VXL - CA92243L2066 - Common Stock
VXL.CA Key Statistics, Chart & Performance
The current stock price of VXL.CA is 0.18 CAD. In the past month the price increased by 5.88%. In the past year, price increased by 1100%.
VXL.CA Latest News, Press Relases and Analysis
VXL.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 426.15M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 404.80M | ||
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 322.55M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 152.76M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 123.45M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 28.63 | 62.79M | ||
| NRX.CA | NUREXONE BIOLOGIC INC | N/A | 57.76M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.88M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 28.82M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 27.24M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 18.40M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 11.34M |
Related stock screener links
About VXL.CA
Company Profile
Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The company has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The company exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Company Info
VAXIL BIO LTD
559 Briar Hill Avenue,
TORONTO ONTARIO M5X 1A4 CA
CEO: David Goren
Employees: 0
VAXIL BIO LTD / VXL.CA FAQ
What does VAXIL BIO LTD do?
Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The company has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The company exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
What is the stock price of VAXIL BIO LTD today?
The current stock price of VXL.CA is 0.18 CAD. The price decreased by -5.26% in the last trading session.
Does VAXIL BIO LTD pay dividends?
VXL.CA does not pay a dividend.
How is the ChartMill rating for VAXIL BIO LTD?
VXL.CA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists VXL stock?
VXL.CA stock is listed on the TSX Venture Exchange exchange.
VXL.CA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VXL.CA. When comparing the yearly performance of all stocks, VXL.CA is one of the better performing stocks in the market, outperforming 99.42% of all stocks.
VXL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VXL.CA. No worries on liquidiy or solvency for VXL.CA as it has an excellent financial health rating, but there are worries on the profitability.
VXL.CA Financial Highlights
Over the last trailing twelve months VXL.CA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -109.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.2% | ||
| ROE | -14.33% | ||
| Debt/Equity | 0 |